Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements
Patients with type 2 diabetes (T2D) are at risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). We investigated the prevalence of compensated advanced chronic liver disease (cACLD) and steatosis in patients with T2D using the new non-invasive diagnostic methods of she...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/12/2/323 |
| _version_ | 1827344105525477376 |
|---|---|
| author | Mislav Barisic-Jaman Marko Milosevic Viktoria Skurla David Dohoczky Josip Stojic Petra Dinjar Kujundzic Maja Cigrovski Berkovic Ana Majic-Tengg Ana Matijaca Tomo Lucijanic Mirjana Kardum-Pejic Vlatka Pandzic Jaksic Srecko Marusic Ivica Grgurevic |
| author_facet | Mislav Barisic-Jaman Marko Milosevic Viktoria Skurla David Dohoczky Josip Stojic Petra Dinjar Kujundzic Maja Cigrovski Berkovic Ana Majic-Tengg Ana Matijaca Tomo Lucijanic Mirjana Kardum-Pejic Vlatka Pandzic Jaksic Srecko Marusic Ivica Grgurevic |
| author_sort | Mislav Barisic-Jaman |
| collection | DOAJ |
| description | Patients with type 2 diabetes (T2D) are at risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). We investigated the prevalence of compensated advanced chronic liver disease (cACLD) and steatosis in patients with T2D using the new non-invasive diagnostic methods of shear wave measurements (SWMs) and attenuation (ATT) measurements in comparison with those of vibration-controlled transient elastography (VCTE) and the controlled attenuation parameter (CAP), which served as the reference methods. Among 214 T2D patients, steatosis at any grade and cACLD were revealed in 134 (62.6%) and 19 (8.9%) patients, respectively. SWMs showed a high correlation with VCTE (Spearman’s <i>ρ</i> = 0.641), whereas SWMs produced lower (mean of −0.7 kPa) liver stiffness measurements (LSMs) overall. At a LSM of >11.0 kPa (Youden), SWMs had an AUROC of 0.951 that was used to diagnose cACLD (defined as a LSM of >15 kPa through VCTE) with 84.2% sensitivity and 96.4% specificity. The performance of ATT measurements in diagnosing liver steatosis at any grade (defined as the CAP of ≥274 dB/m) was suboptimal (AUROC of 0.744 at the ATT measurement cut-off of >0.63 dB/cm/MHz (Youden) with 59% sensitivity and 81.2% specificity). In conclusion, the prevalence of liver steatosis and previously unrecognized cACLD in patients with T2D is high and SWMs appear to be a reliable diagnostic method for this purpose, whereas further investigation is needed to optimize the diagnostic performance of ATT measurements. |
| first_indexed | 2024-03-07T22:42:11Z |
| format | Article |
| id | doaj.art-f7de63e0d1104351a7ccef2f0b9d38d5 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-07T22:42:11Z |
| publishDate | 2024-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-f7de63e0d1104351a7ccef2f0b9d38d52024-02-23T15:08:29ZengMDPI AGBiomedicines2227-90592024-01-0112232310.3390/biomedicines12020323Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation MeasurementsMislav Barisic-Jaman0Marko Milosevic1Viktoria Skurla2David Dohoczky3Josip Stojic4Petra Dinjar Kujundzic5Maja Cigrovski Berkovic6Ana Majic-Tengg7Ana Matijaca8Tomo Lucijanic9Mirjana Kardum-Pejic10Vlatka Pandzic Jaksic11Srecko Marusic12Ivica Grgurevic13Department of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Endocrinology, Diabetes, Diseases of Metabolism and Clinical Pharmacology, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Endocrinology, Diabetes, Diseases of Metabolism and Clinical Pharmacology, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Endocrinology, Diabetes, Diseases of Metabolism and Clinical Pharmacology, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Endocrinology, Diabetes, Diseases of Metabolism and Clinical Pharmacology, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Endocrinology, Diabetes, Diseases of Metabolism and Clinical Pharmacology, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Endocrinology, Diabetes, Diseases of Metabolism and Clinical Pharmacology, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Endocrinology, Diabetes, Diseases of Metabolism and Clinical Pharmacology, University Hospital Dubrava, 10000 Zagreb, CroatiaDepartment of Gastroenterology, Hepatology and Clinical Nutrition, University Hospital Dubrava, 10000 Zagreb, CroatiaPatients with type 2 diabetes (T2D) are at risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD). We investigated the prevalence of compensated advanced chronic liver disease (cACLD) and steatosis in patients with T2D using the new non-invasive diagnostic methods of shear wave measurements (SWMs) and attenuation (ATT) measurements in comparison with those of vibration-controlled transient elastography (VCTE) and the controlled attenuation parameter (CAP), which served as the reference methods. Among 214 T2D patients, steatosis at any grade and cACLD were revealed in 134 (62.6%) and 19 (8.9%) patients, respectively. SWMs showed a high correlation with VCTE (Spearman’s <i>ρ</i> = 0.641), whereas SWMs produced lower (mean of −0.7 kPa) liver stiffness measurements (LSMs) overall. At a LSM of >11.0 kPa (Youden), SWMs had an AUROC of 0.951 that was used to diagnose cACLD (defined as a LSM of >15 kPa through VCTE) with 84.2% sensitivity and 96.4% specificity. The performance of ATT measurements in diagnosing liver steatosis at any grade (defined as the CAP of ≥274 dB/m) was suboptimal (AUROC of 0.744 at the ATT measurement cut-off of >0.63 dB/cm/MHz (Youden) with 59% sensitivity and 81.2% specificity). In conclusion, the prevalence of liver steatosis and previously unrecognized cACLD in patients with T2D is high and SWMs appear to be a reliable diagnostic method for this purpose, whereas further investigation is needed to optimize the diagnostic performance of ATT measurements.https://www.mdpi.com/2227-9059/12/2/323MASLDdiabetes mellitusultrasoundelastographyliver fibrosisliver steatosis |
| spellingShingle | Mislav Barisic-Jaman Marko Milosevic Viktoria Skurla David Dohoczky Josip Stojic Petra Dinjar Kujundzic Maja Cigrovski Berkovic Ana Majic-Tengg Ana Matijaca Tomo Lucijanic Mirjana Kardum-Pejic Vlatka Pandzic Jaksic Srecko Marusic Ivica Grgurevic Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements Biomedicines MASLD diabetes mellitus ultrasound elastography liver fibrosis liver steatosis |
| title | Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements |
| title_full | Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements |
| title_fullStr | Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements |
| title_full_unstemmed | Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements |
| title_short | Compensated Advanced Chronic Liver Disease and Steatosis in Patients with Type 2 Diabetes as Assessed through Shear Wave Measurements and Attenuation Measurements |
| title_sort | compensated advanced chronic liver disease and steatosis in patients with type 2 diabetes as assessed through shear wave measurements and attenuation measurements |
| topic | MASLD diabetes mellitus ultrasound elastography liver fibrosis liver steatosis |
| url | https://www.mdpi.com/2227-9059/12/2/323 |
| work_keys_str_mv | AT mislavbarisicjaman compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT markomilosevic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT viktoriaskurla compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT daviddohoczky compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT josipstojic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT petradinjarkujundzic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT majacigrovskiberkovic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT anamajictengg compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT anamatijaca compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT tomolucijanic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT mirjanakardumpejic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT vlatkapandzicjaksic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT sreckomarusic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements AT ivicagrgurevic compensatedadvancedchronicliverdiseaseandsteatosisinpatientswithtype2diabetesasassessedthroughshearwavemeasurementsandattenuationmeasurements |